NFE2L2 and non-small cell lung carcinoma: A phase 1 study combining sapanisertib (TORC1/2 inhibitor) + CB-839 to determine recommended dose and preliminary efficacy in advanced NSCLC, focusing on NFE2L2/KEAP1 subgroups [115].